Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB-Dentalac
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
AB-Dentalac is a probiotic formula developed by AB-BIOTICS specifically designed to support oral health and restore the oral microbiota balance. The product typically consists of a combination of specific lactic acid bacteria strains, notably *Lactobacillus plantarum* CECT 7481 and *Lactobacillus brevis* CECT 7480. Its mechanism of action involves the competitive exclusion of oral pathogens such as *Porphyromonas gingivalis*, the production of antimicrobial compounds, and the modulation of the host's local inflammatory response. AB-Dentalac is indicated for the management of gingivitis, periodontitis, and halitosis (bad breath), and is also used to promote faster recovery following oral surgery by preventing dysbiosis.
- Brand names
- AB-DentalacDentisani
- Other names
- AB-Dentalac
Beyond the preview
Go deeper on AB-Dentalac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB-Dentalac.